DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated
